DEVELOPMENT OF LOBEGLITAZONE AS ANTI-DIABETIC MEDICATION
Aakarsh Gupta, Manushree Rawat, Rajat Rawat, Yogesh Joshi · 2023
Diabetes mellitus is a chronic metabolic disorder affecting millions and its prevalence is increasing worldwide. To address the challenges posed by existing anti-diabetic medications, researchers have been exploring novel compounds to improve treatment outcomes. Lobeglitazone, a third-generation Thiazolidinedione (TZD), has emerged as a potential candidate in the management of diabetes. It acts as a selective peroxisome proliferator-activated receptor gamma (PPARγ) agonist, enhancing insulin sensitivity in peripheral tissues. Clinical trials have demonstrated Lobeglitazone's efficacy in lowering blood glucose levels, both as a monotherapy and with other anti-diabetic drugs. Moreover, its favorable safety profile, including reduced risk of weight gain and edema compared to older TZDs, makes it an attractive option for patients. While Lobeglitazone represents a significant advancement in anti-diabetic medication, further research and long-term studies are essential to establish its precise role in diabetes management and ensure optimal patient care. The ongoing efforts to develop innovative medications highlight the continuous pursuit of improving diabetes treatment and enhancing the better quality loifestyle for those living with this severe condition.